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ARTICLE
The WNT target SP5 negatively regulates WNT
transcriptional programs in human pluripotent
stem cells
Ian J. Huggins1, Tomas Bos1, Olivia Gaylord1, Christina Jessen1, Brianna Lonquich1, Angeline Puranen1,
Jenna Richter1, Charlotte Rossdam1, David Brafman2, Terry Gaasterland 3 & Karl Willert 1
The WNT/β-catenin signaling pathway is a prominent player in many developmental pro-
cesses, including gastrulation, anterior–posterior axis specification, organ and tissue devel-
opment, and homeostasis. Here, we use human pluripotent stem cells (hPSCs) to study the
dynamics of the transcriptional response to exogenous activation of the WNT pathway. We
describe a mechanism involving the WNT target gene SP5 that leads to termination of the
transcriptional program initiated by WNT signaling. Integration of gene expression profiles of
wild-type and SP5 mutant cells with genome-wide SP5 binding events reveals that SP5 acts to
diminish expression of genes previously activated by the WNT pathway. Furthermore, we
show that activation of SP5 by WNT signaling is most robust in cells with developmental
potential, such as stem cells. These findings indicate a mechanism by which the develop-
mental WNT signaling pathway reins in expression of transcriptional programs.
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Animal development requires precise coordination amongthe cells of the embryo to balance cell division and pat-terning, and thereby ensure the generation of all adult
organs and tissues in their proper locations and proportions.
Extra-cellular signaling molecules mediate cell–cell communica-
tion to control fundamental embryonic processes such as for-
mation of the primitive streak, gastrulation movements, and
establishment of the anterior/posterior and dorsal/ventral axes.
The WNT/β-catenin signaling pathway (commonly referred to as
the canonical WNT pathway), which is highly conserved across
all metazoan life forms, is essential for embryonic development
and, later in life, for adult tissue homeostasis and regeneration.
Deregulation of this pathway causes severe congenital defects,
underlies multiple diseases and disorders, and frequently drives
oncogenic transformation (reviewed in refs. 1–3).
Developmental signaling pathways, such as the WNT/β-cate-
nin pathway, initiate signaling cascades that culminate in the
expression of many target genes that subsequently mediate
developmental programs. To exert temporal control over these
highly coordinated developmental processes, these same signaling
pathways initiate negative feedback loops that act to desensitize
the cell to the signal. Less understood and studied are the
mechanisms by which the transcriptional program previously
activated by a pathway are diminished and eventually terminated
so that a cell can properly respond to subsequent signaling inputs.
The prevailing view is that changes in the epigenetic landscape
through chromatin modifications and DNA methylation lead to
poising and silencing of genes, thereby altering the transcriptional
profile of a cell. However, examples of direct connections between
developmental signaling pathways and activity of epigenetic
modifiers remain scarce.
Recent studies using pluripotent stem cells, such as human
embryonic and induced pluripotent stem cells (collectively
referred to here as hPSCs), have led to important insights on how
developmental programs progress to generate mature cell types,
such as cardiomyocytes and pancreatic beta cells (reviewed in ref.
4). Such studies established that efficient and directed differ-
entiation of hPSCs requires tight temporal control over specific
signaling pathways, including those stimulated by WNT, FGF,
SHH, NOTCH, and TGFβ. For example, efficient generation of
definitive endoderm (DE), a precursor cell population of liver,
pancreas, and gut, from hPSCs requires initial activation and
subsequent inactivation of WNT/β-catenin signaling5, 6.
Here we present data supporting a mechanism by which
WNT/β-catenin signaling acts to diminish and thereby terminate
its own transcriptional program. Using hPSCs, we dissect the
temporal changes in gene expression upon WNT pathway acti-
vation. The SP5 transcription factor emerged as a critical
downstream WNT target that acts to rein in expression of a large
swath of genes previously activated by the WNT signal. These
findings suggest a mechanism by which a developmental signal-
ing pathway acts to dynamically regulate gene expression.
Results
Identification of SP5 as a WNT/β-catenin target gene. To study
the effects of WNT signaling in hPSCs, we analyzed the tran-
scriptomes of cells treated for 12, 24, and 48 h with Wnt3a by
high-throughput RNA sequencing (RNA-Seq). Morphological
changes consistent with cellular differentiation are apparent by
microscopy 48 h post treatment (Fig. 1a). Immunofluorescence
(IF) analysis and flow cytometry demonstrate increased expres-
sion of differentiation markers, such as SOX17 (Fig. 1b), and a
concomitant loss of expression of pluripotency markers, such as
FZD77, 8 (Supplementary Fig. 1a), SSEA4, and TRA1-81 (Sup-
plementary Fig. 1b). Clustering of significantly differentially
expressed genes (Supplementary Data 1) according to change in
percent maximum reads per kilobase per million mapped reads
(RPKM) reveal four clear waves of gene expression (Fig. 1c): (i)
decreased expression of genes involved in pluripotency and
neural differentiation, (ii) transient upregulation of mesendo-
dermal genes, (iii) upregulation of genes involved in primitive
endoderm, and (iv) late upregulation genes expressed in DE and
the tail bud.
To identify potential downstream transcriptional programs
under the control of WNT signaling, we focused on the top 10
upregulated genes encoding known transcription factors (Fig. 1d;
Supplementary Fig. 1c). Chromatin immunoprecipitation fol-
lowed by sequencing (ChIP-Seq) for histone H3 lysine 4 tri-
methylation (H3K4me3), a mark enriched in promoters of
actively transcribed genes9, reveal SP5 to be potently activated by
WNT signaling (Fig. 1d; Supplementary Fig. 1d). Reverse
transcription quantitative PCR (qPCR) confirm the induction of
SP5 mRNA by recombinant Wnt3a protein in a time- and dose-
dependent fashion (Supplementary Fig. 1e, f). AXIN2, a well-
known universal target of the WNT pathway10, 11, is also induced
by Wnt3a, albeit at lower levels and only transiently compared to
SP5 (Supplementary Fig. 1e, f). Furthermore, expression of SP5,
like AXIN2, is induced in a dose-dependent fashion by a small-
molecule inhibitor of GSK3β (CHIR98014, Supplementary
Fig. 1g), indicating that SP5 expression is likely dependent on
transactivation by β-catenin and not another WNT-dependent
signaling cascade, consistent with previous studies12–14.
SP5 encodes a member of the SP/KLF family of Zinc-finger
DNA binding proteins that recognizes GC-rich elements, referred
to as GC boxes (consensus sequence GGGCGG). SP5, which
shares limited domain homology with the ubiquitous SP1
transcription factor (Supplementary Fig. 1h), has previously been
described as a WNT/β-catenin target gene12, 14–18. Immunoblot-
ting with an antibody directed against the amino-terminus of SP5
(Supplementary Fig. 1h) demonstrates that SP5 protein levels
increase substantially upon Wnt3a treatment (Fig. 1e; Supple-
mentary Fig. 1i), consistent with the increase in SP5 mRNA
(Supplementary Fig. 1e, f). In contrast, SP1 shows no change in
protein levels, again consistent with our RNA-Seq data. IF
analysis reveals that SP5 protein is largely localized to the nucleus
(Fig. 1f), as expected for a transcription factor.
Studies in mouse embryos and ES cells established that Sp5 and
Sp8 act redundantly as key effectors of the Wnt3a/β-catenin
pathway16, 19. Therefore we mined our RNA-Seq data set for the
expression of all known members of the SP/KLF family of
transcription factors to determine whether WNT signaling alters
the expression of other family members. In contrast to the strong
induction of SP5, we observe little or no change in the expression
of other SP/KLF family genes, including SP8 (Fig. 1g), suggesting
a unique and potentially non-redundant role for SP5 downstream
of WNT pathway activation in a human system.
SP5 regulates differentiation of hPSC. To study the role of SP5
downstream of WNT signaling in hPSCs, we generated mutations
in the SP5 gene using the CRISPR-Cas9 system. The mutagenesis
strategy, which was designed to delete the sequence encoding the
Zinc-finger domain of SP5 (Fig. 2a), yielded 5 out of 36 clones
carrying deletions in both SP5 alleles (Supplementary Fig. 2a, b).
We expanded two clones, dZF1 and dZF2 (deleted Zinc Finger)
with normal karyotypes (Supplementary Fig. 2c) and confirmed
the absence of full-length SP5 proteins by immunoblotting
(Fig. 2b; Supplementary Fig. 2d). Levels of a truncated SP5
protein in dZF mutant cells is significantly lower than that of
wild-type (WT) SP5 protein, making dominant negative activities
unlikely.
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Fig. 1 Identification of SP5 as a highly responsive WNT/β-catenin target gene in hPSCs. a Cell morphology changes in response to Wnt3a treatment.
HESCs (H1/WA01) were treated with 1 nM Wnt3a for the indicated times and imaged using phase contrast microscopy. Scale bar= 100 μm. b
Immunofluorescence (IF) for a differentiation marker. hESCs were treated with 1 nM Wnt3a for 2 days and analyzed by IF for SOX17 expression. Scale bar
= 100 μm. c Heatmap of genes with significant changes in expression upon Wnt3a treatment. HESCs were treated with 1 nMWnt3a for the indicated times
and RNA was isolated and analyzed by RNA-Seq. About 511 genes with significant differential expression in response to Wnt3a fell into four main clusters
i–iv. Refer to Supplementary Data 1 for complete gene set. d Transcription factors with greatest differential expression in response to Wnt3a. The top 10
genes encoding transcription factors were sorted by percent maximum reads per kilobase per million mapped reads (RPKM). ChIP-Seq analysis indicated
that the SP5 promoter region shows a significant change in the histone mark H3K4me3 upon Wnt3a signaling. Supplementary Fig. 1c, d provides additional
information about these transcription factors and display the genome browser tracks of all 10 genes for this histone mark. e SP5 protein accumulation in
response to Wnt3a treatment. HESCs were treated with 1 nM Wnt3a for the indicated times and nuclear extracts were immunoblotted for SP5, SP1, or β-
actin (a loading control). kD kilo Daltons. f Immunofluorescence of SP5. HESCs were treated with Wnt3a (1 nM) for 24 h and cells were fixed and stained
for SP5 (red, rabbit anti-SP5) and DNA (blue, Hoechst). Untreated cells were incubated with an equivalent volume of WNT storage buffer. Scale bar= 100
μm. g Expression of SP/KLF family members in hESCs treated with Wnt3a. RPKM values for all SP/KLF genes were extracted from the RNA-Seq data
described in c and displayed as a heatmap
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As a measure of pluripotency, we injected WT and dZF cells
into immune-compromised mice; both cell lines produce
teratomas that express derivatives of all three germ layers, as
assessed by histological analysis (Supplementary Fig. 2e, f). This
experiment demonstrated that dZF cells are pluripotent, however,
this assay is not sufficiently quantifiable to detect changes in
differentiation potential.
To quantify multi-lineage differentiation potential of SP5
mutant hPSCs, we generated embryoid bodies (EBs) using
established assays. Both WT and dZF hPSCs form tight cell
aggregates within 1 day. Upon extended culturing, the dZF EBs are
larger in size than their WT counterparts (Fig. 2c; Supplementary
Fig. 2g). At 8–10 days of culture, dZF EBs acquire an increasingly
rough and uneven morphology compared to the characteristic
smooth surface of WT EBs (Fig. 2c; Supplementary Fig. 2h). Gene
expression analysis demonstrates that dZF EBs express signifi-
cantly higher levels of endodermal markers FOXA2 and SOX17,
and of primitive streak markers MIXL1 and T (BRY) relative to
WT EBs (Fig. 2d; Supplementary Fig. 2i). In contrast, expression
of the early ectodermal marker PAX6 is significantly elevated in
WT cells relative to dZF cells (Fig. 2d). Expression of another
ectodermal marker, SOX1, is only subtly affected (Supplementary
Fig. 2i). Together, this gene expression analysis indicates that SP5
is critical for the proper differentiation of hPSCs.
As an additional measure of in vitro differentiation potential,
we induced differentiation of adherent WT and dZF cells for up
to 10 days. Transcriptome analysis by RNA-Seq reveals that WT
and dZF cells diverge increasingly over the course of differentia-
tion (Fig. 2e). These EB formation and monolayer differentiation
assays demonstrate that SP5-deficient cells are capable of multi-
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Fig. 2 SP5 is required for normal hPSC differentiation. a Schematic of the SP5 gene. A deletion of the sequence encoding the C2H2 Zinc-finger DNA binding
domain was generated using CRISPR-Cas9 with two guide RNAs (designated by red arrowheads). Gene structure: thin lines for intron and intergenic
regions, medium lines for non-coding exonic sequence, and thick lines for open reading frame. The position of genotyping primers is indicated by arrows. b
Wild-type and mutant SP5 protein detection. Lysates from unstimulated (−) and CHIR-stimulated (+) WT and SP5 mutant (dZF1 and 2) hESCs were
analyzed by immunoblotting. Short (i) and long (ii) exposures of the same immunoblot are shown. CHIR= CHIR98014; kD kilo Daltons. c Altered EB
formation from SP5mutant cell lines. SP5 mutant EBs acquire abnormal morphologies at later time points. Scale bar= 100 μm. d Altered gene expression in
SP5 mutant EBs. RNA was isolated from EBs at the indicated days after initiation of differentiation and analyzed by qPCR for expression of markers
indicative of endoderm (FOXA2), mesoderm (MIXL1), and ectoderm (PAX6). RQ relative quantity. (Error bars are SEM for four technical replicates;
Student’s t test: **p< 0.01; ***p< 0.001; ****p< 0.0001). e Altered gene expression in monolayer differentiation of SP5 mutant cells. WT and SP5 mutant
(dZF 1 and 2) hESCs were differentiated through removal of FGF2 and addition of fetal bovine serum. RNA was extracted at 3 and 10 days after initiation of
differentiation and analyzed by RNA-Seq. Correlation matrices representing 5253 differentially expressed genes indicate increased divergence of WT (two
independent differentiations) and dZF cells at days 3 and 10 of differentiation
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lineage differentiation, but exhibit significantly altered lineage
allocation compared to WT hPSCs.
SP5 binds to select locations across the genome. To identify
genes directly regulated by SP5, we performed ChIP-Seq from cells
treated with Wnt3a for 24 h, a time point at which SP5 protein
was highly elevated (Fig. 1e). Previous work demonstrated that
SP5 binds to the same DNA motif as SP1 and competes directly
with SP1 for binding to certain loci17. Since SP5 is a direct target
of WNT signaling and largely resembles a transcriptional
repressor, Fujimura and colleagues hypothesized that WNT
downregulates SP1 target genes through the upregulation of SP5,
as demonstrated for expression of the Cdkn1a (p21) gene. Because
of this observed competition between SP1 and SP5, we also per-
formed a SP1 ChIP-Seq analysis on hPSCs treated with Wnt3a.
We sequenced co-immunoprecipitated DNA from the SP5 and
SP1 pull downs, mapped high-quality reads to the human refer-
ence genome assembly GRCH37/hg19 and identified SP5 and SP1
binding sites using the computational method MACs20.
In contrast to SP1, which binds to a large number of sites
across the genome, SP5 binding is significantly more selective
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(Fig. 3a). We identify no significant SP5 binding events in
untreated cells and 662 SP5 binding events in Wnt3a-treated cells
(Fig. 3b; Supplementary Data 2). In contrast, we observe 37,306
and 24,747 SP1 binding events in untreated and Wnt3a-treated
cells, respectively (Fig. 3b). These numbers are consistent with
available ENCODE data sets for SP1 ChIP-Seq in H1 hESCs21. Of
the 662 SP5 binding sites, 475 overlap with sites bound by SP1,
lending support to the hypothesis that SP5 and SP1 compete for
binding at these sites. Of these binding events, a majority map
within 2000 bases of transcriptional start sites (TSS, Fig. 3c); in
contrast, only 4 of the 187 SP5 binding sites that do not overlap
SP1 sites map near TSS (Fig. 3c). Further, SP5 peaks without an
overlapping SP1 peak are more distant from TSS than SP5 peaks
with an overlapping SP1 peak (Supplementary Fig. 3a).
Motif enrichment analysis of SP5 binding sites overlapping SP1
peaks (n= 475) reveals that the most highly represented sequence
motif in each peak resembles the previously identified GC-box
motif (Fig. 3d, panel i)22. The central base at position 5 or 6 of the
motif, flanked by Gs, is variable with A more prevalent than C
(Fig. 3d, panel i; Supplementary Fig. 3b, panels i and ii). The
motif derived from SP5 peaks lacking an overlapping SP1 peak (n
= 187) differs from this canonical GC box, with a lower frequency
of G surrounding positions 5 and 6 (Fig. 3d, panel ii;
Supplementary Fig. 3b, panel iii). Summits of SP1 peaks were
most highly enriched for the canonical GC box (Fig. 3d, panel iii).
As expected, the majority of SP1 and SP5 peaks contains this
canonical GC-box motif, whereas a lower fraction of SP5 peaks
lacking SP1 peaks contains this motif (Fig. 3e).
We observed that SP1 binding is significantly reduced at sites
co-occupied by SP5 upon Wnt3a treatment (Fig. 3f). In contrast,
there is no significant decline upon Wnt treatment in SP1 binding
at sites that are not occupied by SP5. Therefore, SP5 only
competes with SP1 at a select subset of sites and does not act
globally to antagonize SP1 binding.
Integration of gene expression changes with SP5 binding. To
further investigate the function of SP5 downstream of WNT/β-
catenin signaling, we compared gene expression profiles in WT
and dZF mutant cells treated with Wnt3a. Principal component
analysis on this RNA-Seq data confirms that mutant cells are
more alike to each other than to WT (Supplementary Fig. 4a).
Consistent with results shown in Fig. 2, SP5 mutant cells induce
significantly higher levels of expression of genes associated with
formation of primitive and DE (Fig. 4a, clusters iii and iv; com-
plete expression data provided in Supplementary Data 3). Genes
with significant changes in gene expression upon Wnt3a treat-
ment also exhibit the largest increase in expression in SP5 mutant
cells (Fig. 4b), indicating that SP5 exerts an inhibitory effect on
these genes.
Consistent with this model, a significant proportion of the
genes with highest degrees of expression changes upon Wnt3a
stimulation are associated with a SP5 peak. Among the top 2081
genes with significant changes in expression (gene list A, p-value
< 0.05), 161 genes have a nearby SP5 peak, representing a 2.3-fold
enrichment relative to all human genes (7.7 % (161 of 2081) vs.
3.3% (774 of 23,135), p< 1.6E−19). We observe a clear
enrichment of genes with SP5 peaks in increasingly refined gene
sets, from 10.4% (gene list B, 104 of 1045) to 13.1% (gene list C,
67 of 511) and to 15.5% (gene list D, 9 of 58) (Fig. 4c; complete
lists of genes provided in Supplementary Data 4). In addition,
gene ontology (GO) analysis (http://geneontology.org) reveals
that genes with associated SP5 peaks are enriched for genes of the
GO term “primitive streak formation” (Fig. 4d; Supplementary
Fig. 4b).
The observation that SP5 peaks are associated with Wnt3a
target genes suggest a potential mechanism for the high selectivity
of SP5 binding compared to SP1, namely that SP5 interacts with
components of the WNT transcriptional response, such as β-
catenin. To test this possibility, we employed a proximity ligation
method using the engineered peroxidase APEX223. Overexpres-
sion of a SP5–APEX2 fusion protein leads to efficient labeling of
β-catenin with biotin, indicating that these two proteins are in
close proximity (Supplementary Fig. 4c). Serving as a specificity
control, β-actin, a highly abundant protein, is not labeled. These
observations suggest a mechanism by which SP5 is recruited to
genomic binding sites occupied by SP1 in the proximity of β-
catenin sites, as is the case for Wnt target genes. These findings
are consistent with those of a previous study showing a direct
interaction between SP5 and β-catenin19.
A recent study in mouse cells identified 892 genes with an
associated Sp5 peak and differential expression Sp5 overexpres-
sion, of which 876 had human homologs measured in our study.
Of our list of 746 genes with an associated SP5 peak (Fig. 4c;
Supplementary Data 2), 76 genes are common with this mouse
gene list (Supplementary Fig. 4d). This overlap contains many of
the genes identified to be most significant in our analysis (18 of
67, gene list C), including AXIN2, GATA6, NODAL, SP5, T, and
TBX3 (Supplementary Data 2). All four lists of genes with
expression changes in response to Wnt3a are enriched in SP5
peaks in both the mouse study and ours, indicating the SP5 target
genes found in both studies are relevant to regulating response to
WNT signaling.
Using qPCR, we confirmed that genes with an associated SP5
peak, such as SP5 itself (Fig. 4e), AXIN2, AMOTL2, GPR37, GSC,
MIXL1, NODAL, and T (Supplementary Fig. 5) show significant
upregulation in expression upon Wnt3a treatment in SP5 mutant
cells. In contrast, genes without an associated SP5 peak, such as
SOX1, exhibit no significant expression changes between WT and
dZF cells (Supplementary Fig. 5). Furthermore, upon prolonged
Fig. 3 Genome-wide mapping of SP5 binding sites. a Representative example of SP1- and SP5-chromatin binding. A segment of chromosome 4 illustrates
the highly selective nature of SP5 binding relative to the ubiquitous transcription factor SP1. PLK4 serves a representative example of SP1 and SP5 binding in
untreated and Wnt3a-treated cells. b A majority of SP5 peaks overlap with SP1 binding sites. A Venn diagram illustrates that 475 SP5 peaks overlapped
with SP1 peaks. SP1 bound thousands of targets throughout the genome, whereas SP5 bound a select number of targets, including unique sites and sites
shared with SP1. The complete list of SP5 peaks is provided in Supplementary Data 2. c A majority of SP5 binding sites map near transcriptional start sites.
The schematic of a generic gene structure provides color-coding for the pie charts. Genomic binding locations of SP5 are categorized as transcriptional
start site (TSS, defined as 2 kb upstream and downstream of TSS), exon, intron, and intergenic. d Motif analysis of SP5 peaks. SP5 binding events were
analyzed for overrepresented sequence motifs using MEME. (i) The most overrepresented motif for the 475 SP5 peaks with an overlapping SP1 peak
closely matches the GC box. (ii) The most overrepresented motif for the 187 SP5 peaks lacking an overlapping SP1 peak diverges from the canonical GC
box. (iii) The most overrepresented motif for SP1 binding summits matches the GC box. eMotif enrichment for SP1 and SP5 binding events. The fractions of
peaks matching the motif in d (i) are provided for all SP1 peaks (SP1 All), SP5 peaks with overlapping SP1 peaks (SP5 w/ SP1), all SP5 peaks (SP5 All), and
SP5 peaks lacking an overlapping SP1 peak (SP5 w/o SP1). f SP5 and SP1 compete for binding at select sites. The normalized average peak score is provided
for all SP1 peaks (SP1 peaks All), SP1 peaks that overlap with SP5 peaks (SP1 peaks with SP5 peaks) and for all SP5 peaks (SP5 peaks) from cells that were
untreated or Wnt3a-treated
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Wnt3a treatment, expression of Wnt targets, such as SP5,
declines; this negative feedback is not observed in SP5 mutant
cells (Fig. 4f). These data provide evidence that SP5 acts to
downregulate expression of genes that are activated upon WNT
pathway activation.
SP5 is a Wnt target in cells with developmental potential. As
observed in various cell types and organisms, activation of WNT/
β-catenin signaling leads to the expression of multiple WNT
antagonist, including AXIN2 (often considered a universal WNT
target gene), APCDD1, DKK1, NKD1, and NOTUM10, 11, 24–27.
We wished to explore to what extent SP5 expression mirrors the
expression of AXIN2 in a variety of cell types. As expected, the
majority of cell lines shows a robust induction of AXIN2 after
Wnt3a stimulation (Fig. 5a; Supplementary Fig. 6a). Cell lines
with strong induction of AXIN2 exhibit poor induction of SP5,
and vice versa (Fig. 5a). In addition, we observed the highest SP5
induction in cell populations with stem cell properties, including
hPSCs, human neural progenitor cells (hNPCs, derived from
hPSCs using established differentiation protocols28, 29) and
embryonic carcinoma cell lines (NCCIT, PA1). Therefore, in
contrast to the universal WNT target AXIN2, robust SP5
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induction correlates strongly with cells that have developmental
potential, such as stem cells.
The observed correlation between SP5 activation and develop-
mental potential suggests that the magnitude of SP5 induction
would decline as hPSCs exit the pluripotent state and acquire an
increasingly differentiated phenotype. To test this possibility, we
differentiated hPSCs over the course of 28 days and at 1-week
intervals evaluated WNT responsiveness by qPCR for SP5 and
AXIN2 (Fig. 5b). We observed that SP5 induction by Wnt3a
relative to untreated cells is highest in undifferentiated cells,
declining sharply in 28-day differentiated cells (Fig. 5c). In
contrast, AXIN2 induction by Wnt3a is only mildly affected
(Fig. 5c).
The decline in SP5 inducibility in differentiated cells may be
due to silencing of the SP5 promoter, loss of a particular TCF/LEF
family transcriptional co-activator, or reduced sensitivity to
Wnt3a. To address whether this desensitization is due to reduced
sensitivity to Wnt3a (e.g., downregulation of Wnt receptors,
upregulation of secreted Wnt antagonists (e.g., DKK, SFRP) or of
negative regulators of the pathway (e.g., AXIN, NAKED, ZNRF3,
RNF43)), we treated cells with the GSK3 inhibitor CHIR98014
(CHIR) to activate the pathway downstream of Wnts and their
receptors. Although CHIR, like Wnt3a, potently activates SP5
expression in undifferentiated cells, it fails to do so in 28-day
differentiated cells (Fig. 5d), demonstrating that the decline in
SP5 induction is by some other means than reduced sensitivity to
Wnt3a. As expected for hPSC differentiation, expression of
POU5F1 and NANOG, key regulators of the pluripotent stem cell
state30–32, declines significantly over the course of the 28-day
differentiation (Fig. 5c). Furthermore, we observe dynamic
changes in expression of germ layer markers SOX17 (endoderm),
T (mesoderm) and PAX6 (ectoderm), indicating loss of
pluripotency (Supplementary Fig. 6b). In addition, we observe a
similar suppression in SP5 (but not of AXIN2) inducibility in
hPSC-derived neurons relative to their parental hNPCs (Supple-
mentary Fig. 6c), further supporting the hypothesis that SP5 is a
WNT/β-catenin target gene in cells with developmental potential.
To identify the mechanisms by which SP5 induction is silenced
over the course of differentiation, we examined the upstream
regulatory regions of the SP5 gene in undifferentiated and
differentiated cells. Using chromatin immunoprecipitation fol-
lowed by PCR (ChIP-PCR), we examined levels of histone H3
lysine 4 di-and tri-methylation (H3K4me2 and H3K4me3), which
mark poised33 and actively transcribed chromatin9, as well as
levels of histone H3 lysine 27 di- and tri-methylation (H3K27me2
and H3K27me3), which mark facultative heterochromatin34, in
the SP5 promoter region. This analysis reveals a significant
reduction in H3K4me2 and H3K4me3 at two loci near the
transcriptional start site of SP5 following differentiation (Fig. 5e),
and subtle to insignificant changes in the repressive marks
H3K27me2 and H3K27me3 (Supplementary Fig. 6d, e). To test
the possibility that SP5 is silenced through the methylation of its
promoter, we measured the change in CpG methylation in the
SP5 promoter (Supplementary Fig. 6f) at the beginning and end
of differentiation. We observe no significant differences in SP5
promoter methylation levels between undifferentiated and
differentiated cells (Supplementary Fig. 6g). Therefore, neither
repressive chromatin marks nor promoter methylation explain
reduced SP5 induction in differentiated cells. Rather, loss of the
critical histone marks H3K4me2 and H3K4me3 likely accounts
for the loss of SP5 induction in response to Wnt3a.
Discussion
Termination of the transcriptional program induced by devel-
opmental signaling pathways is critical to ensure tightly orche-
strated developmental events. While WNT/β-catenin signaling
has known mechanisms to antagonize components of the path-
way, including WNT receptors and the WNT protein itself, and
thereby desensitize cells to subsequent WNT signals, little was
known about how key target genes were subsequently down-
regulated. Here, we have shown that the WNT target gene SP5
has a key role and acts to downregulate expression of many WNT
target genes, including SP5 itself, thereby dampening the tran-
scriptional response initiated by WNT signaling. Such dampening
of gene expression is critical to ensure progression and comple-
tion of developmental programs. Our findings indicate a
mechanism by which developmental signaling pathways are
regulated (summarized in Fig. 6). Prior studies have focused on
the mechanisms by which developmental programs are initiated
and have established that the ability to interpret appropriately
inductive signals from the environment, a phenomenon referred
to as developmental competence, is determined by poising the
transcriptional state of critical developmental regulators.
A common theme in developmental signaling is the activation
of negative feedback systems that ensure the developmental
program is under tight temporal control. In the case of the WNT/
β-catenin signaling pathway, this negative feedback system
involves mechanisms that act at multiple levels on the compo-
nents of the pathway, including the signaling molecule WNT
(SFRPs, DKK, NOTUM), the FZD receptors (RNF43, ZNRF3,
APCDD1), and the intracellular signaling cascade (AXIN2,
NKD). While this system ensures signal desensitization, it does
not act on the expression of many of the previously activated
target genes. SP5 provides a previously unrecognized mechanism
by which a cell downregulates and thereby fine-tunes the
expression of complex transcriptional programs.
A recent study raised the question whether SP5 acts globally to
antagonize SP1 target gene expression17. Our findings demon-
strated that SP5 does not compete with SP1 for target site binding
Fig. 4 SP5 regulates expression of developmental regulators. a Altered gene expression in WNT-treated SP5 mutant cells. A heatmap of gene expression
illustrates differences between WT and SP5 mutant (dZF1 and 2) hESCs. Genes are in order of the clusters identified in Fig. 1c; expression is given as
percent WT maximum RPKM (0, white; 100, blue; ≥100, red). Refer to Supplementary Data 3 for complete gene list. b Representative upregulated genes.
The average change in percent maximum RPKM of dZF 1 and dZF 2 vs. wild-type illustrates upregulation of many developmental regulators (−1, indigo; 0,
white; 1.0, red). Genes in red contain a SP5 peak. *SP5 peaks near FOXA2 and SOX17 were called at a lower confidence (p< 10−4 vs. p< 10−5) and were not
included in the list of 662 SP5 peaks. c SP5 peaks are enriched among genes with the most significant fold changes upon WNT treatment. For each gene
set (A through D), the table provides the p-value for the least significantly changed gene (as described by Trapnell et al.52, 53). Refer to Supplementary
Data 4 for gene lists. The graph indicates the fraction of genes with SP5 peaks among gene sets A through D. d Genes with SP5 peaks are associated with
early embryonic development. Gene ontology (GO) analysis reveals that genes with SP5 peaks of gene set C are highly enriched for genes associated with
“primitive streak formation”. e Validation of upregulated genes. WT and dZF mutant hESCs were treated with 1 nMWnt3a for the indicated times and RNA
was isolated and analyzed by qPCR for expression of SP5. Genome browser tracks illustrate the increase of SP5 binding near the transcriptional start site.
Additional examples are provided in Supplementary Fig. 5. Arrows indicates direction of transcription. RQ relative quantity. (Error bars are SEM for four
technical replicates; Student’s t test: *p< 0.05; **p< 0.01; ****p< 0.0001). f Extended Wnt3a treatment of hPSC. WT and SP5 mutant (dZF2) cells were
treated with Wnt3a for the indicated times and RNA was analyzed by qPCR for SP5 expression
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Fig. 5 Robust SP5 induction is associated with developmental potential. a SP5 and AXIN2 induction in multiple cell lines. Multiple cell lines (Supplementary
Fig. 6a) were treated with Wnt3a (1 nM) for 24 h and expression of AXIN2 and SP5 was quantified by qPCR. Red dots indicate cell types with significant SP5
induction relative to AXIN2 induction (dashed line demarcates boundary, where SP5 induction exceeds AXIN2 induction by 10-fold). b Schematic of
experimental design. Undifferentiated hESCs (H1/WA01) were differentiated for 28 days, cells were treated with Wnt3a on the indicated days, and RNA
was isolated 1 day later for analysis by qPCR. Chromatin and genomic DNA were isolated from undifferentiated and 27-day differentiated cells, and
analyzed by ChIP and bisulfite sequencing. c WNT responsiveness over a differentiation course. Cells were treated with Wnt3a on the indicated days of
differentiation and RNA was analyzed by qPCR for levels of SP5, AXIN2, NANOG, and POU5F1 mRNAs. RQ relative quantity. The bottom graphs represent
the ratios of relative gene expression in Wnt3a-treated vs. untreated cells. (Error bars are SEM for four technical replicates. d Activation of WNT signaling
by GSK3 inhibition fails to overcome desensitization of SP5 responsiveness in differentiated cells. RNA from undifferentiated and 28-day differentiated cells
treated with either buffer (untreated), Wnt3a, or CHIR98014 (CHIR) was analyzed by qPCR for SP5 expression. e ChIP-PCR analysis of the SP5 promoter
region. Cross-linked chromatin was isolated from cells prior to differentiation (Day-1) and on Day 27 of differentiation and immunoprecipitated with
antibodies to the activating histone marks H3K4me2 (left panel) and H3K4me3 (right panel). Enrichment of immunoprecipitated chromatin was quantified
by PCR of two regions of the SP5 promoter, amplicons 1 and 2, the positions of which are indicated in the SP5 gene schematic. Promoter marks H3K3me2
and H3K3me3 are greatly depleted in differentiated cells relative to undifferentiated cells. (Error bars are SEM for four technical replicates; Student’s t test:
*p< 0.05; **p< 0.01; ***p< 0.001)
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on a global scale in hPSCs, but rather is concentrated on a select
subset of genes, a significant fraction of which were differentially
expressed upon WNT pathway activation. Therefore, SP5 pri-
marily acts on dynamically expressed genes and does not disrupt
expression of ubiquitous housekeeping genes that are under
control of SP1.
The role of Sp5 downstream of Wnt signaling was recently
examined in mouse development and embryonic stem cells19.
That study concluded that Sp5 acts in a feed-forward loop to
robustly activate select Wnt target genes, a conclusion that is in
stark contrast to our hypothesis that SP5 acts to rein in expression
of WNT target genes. Aside from the obvious differences in
systems (embryo vs. embryonic stem cells) and organisms (mouse
vs. human), we offer several possible explanations to address the
disparate findings. First, RNA-Seq and ChIP-Seq experiments in
the Kennedy et al.19 study involved overexpression of Sp5 protein,
which may produce activities normally not associated with
endogenously expressed protein. Our studies were performed
using endogenously expressed SP5, the expression of which was
dynamically regulated by activation of the WNT pathway. This
approach allowed us to observe the dynamic changes in gene
expression downstream of WNT signaling such that the antag-
onistic activity of SP5 is only observed later during the signaling
program.
Second, in the Kennedy et al.19 study, loss-of-function phe-
notypes were evaluated in the context of Sp5 and Sp8 double
knockout (DKO). Such DKO mESCs exhibited significantly lower
induction of the Wnt target gene T upon Wnt pathway activation,
in contrast to our SP5 knockout hESCs where WNT target genes,
including T, were consistently upregulated upon Wnt pathway
activation. Although Sp5 and Sp8 are highly related to each other
and may act redundantly during mouse development, these two
proteins may carry distinct functions. Interestingly, we did not
observe robust transcriptional activation of SP8 as previously
observed upon Wnt pathway activation in mESCs16, suggesting
that in hPSCs SP5 function is not redundant with SP8.
Finally, our observations further highlight the clear distinctions
between mESCs and hPSCs that have been the subject of many
studies and reviews (reviewed in ref. 35). It is noteworthy that
naive mESC exhibit higher basal WNT signaling activity relative
to the primed hPSC used in these studies29, 36, 37. Taken together,
the variable results described by the two studies can be attributed
in part to differences in systems and approaches. Nonetheless, it
should be emphasized that both studies support SP5 as a mod-
ulator of response to WNT signaling. Importantly, intersecting
mouse and human gene sets revealed that highly similar tran-
scriptional programs are under WNT-SP5 control.
This function of SP5 is potentially relevant to other cell
populations capable of self-renewal and differentiation. We found
that induction of SP5 by WNT/β-catenin signaling was most
prominent in cell types with stemness properties, including
hPSCs, hPSC-derived neural progenitor cells (hNPCs), and
pluripotent embryonal carcinoma cell lines (PA1 and NCCIT).
The levels of induction were sharply reduced upon differentiation
of hPSCs to a fibroblast-like population and of NPCs to neurons.
Likewise, all tested cell lines that lack stemness properties
exhibited a relatively minor to absent induction of SP5 upon
WNT treatment. While the mechanism(s) underlying loss of SP5
induction are not completely understood, we showed that a his-
tone mark, H3K4me2, which marks poised33 and actively tran-
scribed chromatin9, is lost as hPSCs differentiate. The observed
correlation between SP5 inducibility and stemness contrasts with
AXIN2, often considered a universal WNT/β-catenin target with
little variability in induction across cell lines. Our data establish a
strong correlation between pluripotency—or developmental
potential—and SP5 inducibility. It is also noteworthy that Sp5 was
identified as a top WNT target gene in Lgr5+ intestinal stem cells
(ISCs)15, which receives a WNT signal from adjoining paneth
cells38, raising the possibility that SP5 inducibility is not restricted
to pluripotent stem cell populations but also occurs in multi-
potent stem cells, such as ISCs. It will be interesting and
important to further examine SP5’s function as a stem cell-
specific WNT target gene using genetic lineage tracing experi-
ments, as has been performed for Axin239–43. Furthermore, it will
be important to examine to what extent this WNT-SP5 regulatory
system is altered in pathological states, such as cancer, where SP5
expression is commonly upregulated44, 45, a situation that likely
impacts the behavior of stem cells.
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Fig. 6Model for SP5’s role in terminating a developmental program. WNT signaling is initiated when WNT engages its receptor encoded by FZD, leading to
stabilization of β-catenin and subsequent activation of target gene expression. WNT target genes encode WNT antagonists (WA), which serve to
downregulate the WNT signaling input as other target genes mediate the WNT effect on a developmental program. During this stage of signaling, SP5
protein accumulates and then competes with SP1 for binding at many WNT target gene sites. The net effect is that SP5 acts to diminish and terminate the
transcriptional program previously activated by WNT
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Methods
Cell lines and culture conditions. Human pluripotent stem cell lines H1
(WA01/NIH Registration Number 0043) and H9 (WA09/NIH Registration
Number 0062) were cultured in E8 culture medium46 on Matrigel (BD Bios-
ciences). Upon passage, cells were dissociated with Accutase (Innovative Cell
Technologies) to single cells and seeded at 2000 cells cm−2 in the presence of the
Rock inhibitor Y-27632, 5 µM (Enzo Life Sciences). Cells were fed daily. Medium
was changed 50% daily. For the formation of EBs, cells were dissociated to single
cells and seeded in ultra-low-attachment culture dishes at 375,000 cells mL−1 with
5 µM Y-27632 in E6 medium (E8 without TGF-β1 and FGF2). Fresh E6 medium
without Rock inhibitor was added daily. Differentiation of hPSCs in monolayer
cultures was achieved by culturing cells in E6 medium supplemented with 20% fetal
bovine serum (Omega Scientific) and Penicillin–Streptomycin (Thermo Fisher
Scientific). Wnt3a protein used in these studies was purified by four-step column
chromatography from conditioned medium harvested from cells engineered to
overexpress Wnt3a47, 48. Untreated cells received an equal volume of WNT storage
buffer (PBS, 1% CHAPS, 1M NaCl). Human neural stem cells (HUES7/NIH
Registration Number 0020) were a gift from Dr. Martin Marsala and derived by
dual inhibition of SMAD signaling28: EBs were formed over 5 days in the presence
of 50 ng mL−1 recombinant mouse noggin (R&D Systems) and 0.5 μM Dorso-
morphin (Tocris Bioscience). After 7 days, neural rosettes were isolated, dissociated
into single cells, and plated onto poly-L-ornithine (10 μg mL−1) and mouse laminin
(5 μg mL−1)-coated dishes with 10 ng mL−1 mouse FGF2 and 10 ng mL−1 mouse
EGF2. Resulting cells were cultured in DMEM/F12 medium (Gibco) with Gluta-
max (Life Technologies), N2 supplement (Life Technologies), B-27 supplement
(Life Technologies), and recombinant FGF2 (20 ng mL−1) (Peprotech). Meso-
dermal progenitor cells were derived and cultured in the Willert laboratory49. All
other cell lines (BT-549, ATCC-HTB-122; H1299, ATCC-CRL-5803; HEK-293,
ATCC-CRL-1573; HeLa, ATCC-CCL-2; K-562, ATCC-CCL-243; NCCIT, ATCC-
CRL-2073; OVCAR-3, ATCC-HTB-161; OVCAR-4, RRID:CVCL_1627; PA1,
ATCC-CRL-1572; SK-OV-3, ATCC-HTB-77; SW480, ATCC-CCL-228; T-47D,
ATCC-HTB-133) were cultured as specified by ATCC (http://www.atcc.org). All
cell lines were tested for mycoplasma contamination. For proximity ligation
experiments, HEK-293 cells were transfected with SP-APEX2, and 48 h post-
transfection cells were incubated for 30 min with Biotin-phenol (Adipogen Life
Sciences) to a final concentration of 500 µM. The labeling reaction was initiated by
adding 1 mM H2O2 and incubated for 1 min, after which cells were lysed as
described below.
Plasmids. The following plasmids were used in these studies: pCMMP IRES-GFP
(modified pCMMP-EnvA/RG-IRES-GFP from Callaway Lab, Salk Institute for
Biological Studies); pCMMP SP5-IRES-GFP (modified pCMMP-EnvA/RG-IRES-
GFP from Callaway Lab, Salk Institute for Biological Studies); pGIPZ shSP5-GFP
#3 (GE Dharmacon, Clone ID: V3LHS_372625); pGIPZ shControl-GFP (GE
Dharmacon, Catalog #: RHS4346); psPAX2 (Addgene); pVSVG (Addgene);
pCMVGP (Addgene); pCas9-EGFP (Cowan Lab, Harvard University); pGRNA
SP5dZF 3′ (modified pGRNA from Cowan Lab); pGRNA SP5dZF 5′ (modified
pGRNA from Cowan Lab); pLEX-SP5-APEX2 (the SP5 open reading frame
flanked by Gateway attB sites was synthesized as a gBlock (Integrated DNA
Technologies), recombined into pDONR221 and subsequently transferred into a
modified pLEX307 plasmid containing the ORF for APEX2 such the transgene
encodes SP5 protein with a C-terminal APEX2).
DNA methylation analysis. Genomic DNA was prepared with the NucleoSpin
Tissue kit (Clontech) according to manufacturer recommendations and bisulfite
converted using the EZ DNA Methylation Kit (Zymo Reseach) according to
manufacturer recommendations. Regions to be sequenced were amplified by PCR,
cloned using the Zero Blunt TOPO PCR Cloning Kit (Thermo Fisher Scientific)
and multiple clones for each region were sequenced. Methylation analysis was
performed using BiQ software. Primer sequences are provided in Supplementary
Table 1.
CRISPR-Cas9 hPS cell targeted mutagenesis. Deletions in the SP5 gene were
generated using CRISPR-Cas9 technology50. Single-guide RNA targets flanking the
zinc-finger coding region of the SP5 locus were selected using CHOPCHOP
(https://chopchop.rc.fas.harvard.edu/about.php) and cloned into pGRNA (see
plasmid list below). Cells were transfected with GeneIn Reagent (GlobalStem)
according to manufacturer recommendations. Briefly, two wells of a six-well plate
were seeded 24 h pre-transfection with 237,000 cells per well in E8 + Y-27632
(5 µM). On the day of transfection, pCas9-GFP (2 µg), pGRNA SP5dZF 5′ (1 µg,
5′-GCAGACCAAGGCCCCCCUGGCGG-3′) and pGRNA SP5dZF 3′ (1 µg,
5′-GGUUAAGCGGGAGGACGCGCGGG-3′) were combined in OptiMEM
medium (400 µL) with GeneIn Red (8 µL) and Blue (8 µL) reagents. Cells were
washed once with dPBS and given fresh E8 culture medium with fetal bovine serum
(10%) and no penicillin–streptomycin. Transfection mix (200 µL) was added
dropwise to the cells, which were returned to a humidified 37 °C, 5% CO2 incu-
bator for 12 h. Cells were washed once with dPBS and fed fresh E8 without
penicillin–streptomycin. GFP-positive cells were isolated by FACS and seeded on a
Matrigel-coated dish in E8 medium at a density that allowed for manual isolation
of single-cell colonies after ~10 days of standard hPSC culture. Single-cell clones
were genotyped by PCR, and chromosome numbers were determined by counting
of metaphase spreads (Cell Line Genetics, Madison, WI). PCR Genotyping Primers:
Forward: 5′-ACAAAGAGGCCTGGTGTTGG-3′, Reverse:
5′-CATTTTGGGAGGCAGGCAAC-3′. The expected size of amplicons for WT
sequence was 609 bp, and for the zinc-finger deleted sequence was ~216 bp, based
on predicted cut site locations.
Embryoid body morphological analyses. For size quantification, EBs cultured in
non-adherent tissue culture dishes were swirled gently, allowed to settle and
imaged in the center of the plate on an inverted phase contrast light microscope
daily for 5 days. The largest diameters of visible EBs were measured using ImageJ
software. For histological analyses, Day 10 EBs were fixed in paraformaldehyde,
embedded in paraffin, sectioned, stained with hematoxylin and eosin and imaged
on a light microscope.
Teratoma assay. Pluripotent stem cells were washed with PBS, dissociated with
Accutase (Life Technologies), centrifuged at 100×g for 3 min. Cell pellet was
resuspended in 300 µL Matrigel (BD Biosciences) to final volume of 600 µL. Cells
were kept on ice prior to injection. Cells were injected subcutaneously at two
locations per nude mouse: the shoulder and hind leg. Injections were performed
using a 1 mL syringe with a 28-gauge needle. Teratoma formation was monitored
over a period of 4–8 weeks until tumors grow to an approximate size of at least 10
mm. Animals were killed and tumors were dissected and fixed in 4% paraf-
ormaldehyde at 4 °C. After 48 h, teratomas were embedded in paraffin before
sectioning. Five-micron sections were stained with hematoxylin and eosin
according to standard protocols. Animal protocol was previously approved by the
University of California San Diego Institutional Animal Care and Use Committee
(Protocol Number S09005, PI A. Muotri, UCSD). Random images were taken from
each sample before analysis. Germ layer distribution was semi-quantified by visual
inspection of H&E-stained sections in a blinded fashion. Differentiated tissue with
defined areas in the teratoma were classified into ectoderm, endoderm, and
mesoderm. The remaining areas remained unclassified.
Preparation of retrovirus and lentivirus. Retrovirus was prepared by transfection
of HEK293T cells with the appropriate viral plasmids along with pCMVGP and
pVSVG. Lentivirus was prepared by transfection of HEK293T cells with the
appropriate viral plasmids along with psPAX2 and pVSVG. Supernatants were
collected and filtered through 0.45 µm filter and virus was concentrated by ultra-
centrifugation in an Optima L-80 XP Ultracentrifuge (Beckton-Dickinson) for 2 h
at 70,000×g in a SW-40 Ti rotor. Pellets were resuspended overnight at 4 °C in
DMEM (Gibco) and frozen at −80 °C until transduction.
RNA expression analysis. RNA expression was measured by quantitative real-
time PCR (qPCR) on a CFX384 thermocycler (Bio-Rad). RNA was collected by
TRIzol Reagent (Life Technologies) or by column purification with RNeasy PLUS
(Qiagen) or NucleoSpin RNA II (CloneTech) Kits according to manufacturer’s
recommendation. Total RNA (50 ng µL−1 final concentration) was used to generate
first strand complimentary DNA (cDNA) using qScript cDNA Supermix (Quanta).
For amplification, cDNA (0.5 µL per well), primers (0.4 µM final concentration),
and SensiFAST Hi-ROX qPCR Master Mix (Bioline) were mixed and dispensed
5 µL per replicate, 4 replicates in a 384-well qPCR plate. Thermal cycler parameters:
initial denaturation, 95 °C for 3 min followed by 40 cycles of annealing and
extension, 60 °C for 5 s and denaturation, 95 °C for 15 s. Primers were validated by
melt curve analysis (60–95 °C, 5 min) and gel electrophoresis of products. Data
were analyzed and statistical analyses performed using CFX Manager (Bio-Rad)
and plotted with Microsoft Excel. All gene expression was normalized to the
expression of an appropriate internal control gene (18 S, GAPDH, RPL13A,
RPL37A, and TBP). QPCR primer sequences are provided in Supplementary
Table 1.
Immunoblotting. For immunoblot analysis of protein expression, cells were
washed once with dPBS, dissociated with PBS + 5mM EDTA and pelleted at 1000
G, 4 °C for 2 min. Cell pellets were resuspended in 500 μL hypotonic lysis buffer
(20 mM Tris-Cl, pH 7.4, 10 mM NaCl, 3 mM MgCl2) and incubated on ice for 15
min. About 25 μL 10% IGEPAL CA-630 (Sigma-Aldrich) was added and tubes
were vortexed for 10 s. Samples were centrifuged at 1000×g for 10 min at 4 °C. The
supernatant (=cytoplasmic fraction) was removed and the pellet (=nuclear frac-
tion) was resuspended in 50 μL cell extraction buffer (1% Triton
X-100, 0.1% SDS, 0.5% deoxycholate, 100 mM NaCl, 1 mM EDTA, 1 mM EGTA,
10% glycerol, 1 mM NaF, 20 mM Na4P2O7, 2 mM Na3VO4, 10 mM Tris-Cl, pH
7.4) freshly supplemented with 1 mM Phenylmethylsulfonyl Fluoride (PMSF,
Sigma-Aldrich P7626) and protease inhibitor cocktail (Sigma-Aldrich, P8340) and
incubated on ice for 30 min, vortexing every 10 min. Samples were centrifuged at
20,000×g, 30 min at 4 °C. The supernatant representing the nuclear fraction, was
transferred to a fresh tube on ice and protein concentration was quantified by
Coomassie protein assay (Thermo Fisher Scientific). About 20 µg of total protein
per lane was resolved by sodium dodecyl sulfate–polyacrylamide gel electrophoresis
(SDS–PAGE), transferred to nitrocellulose, blocked for 1 h at room temperature in
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blocking buffer (TBS, 0.2% Tween-20, 1% BSA, 3% non-fat dry milk) and probed
with the appropriate primary antibodies (see below) in blocking buffer overnight at
4 °C. Protein was detected following incubation with secondary antibodies for 1 h
at room temperature, incubation with Western Lighting ECL Reagent (Perkin-
Elmer), and exposure to autoradiography film. For proximity ligation experiments
with SP-APEX2, transfected HEK-293 treated with Biotin-phenol and H2O2 (see
above under “Cell Lines and Culture Conditions” section) were washed twice with
Quencher Solution (10 mM Sodium Ascorbate, 5 mM Trolox, and 10 mM Sodium
Azide in 1× PBS) and twice with PBS. Cells were collected and lysed in RIPA buffer
containing 10 mM Sodium Ascorbate, 5 mM Trolox, and 10 mM Sodium Azide for
10 min on ice. Lysates were centrifuged for 10 min at 12,000×g, 4 °C. About 20 μL
of cleared supernatant was stored at −80 °C and used as input. To the remaining
supernatant, 200 μL Streptavidin beads (New England Biolabs) were added and
incubated for 1 h with rotation. Beads were washed twice with RIPA buffer, once
with 2 M Urea in 10 mM Tris-HCl pH 8, twice with RIPA buffer and twice with
PBS. Proteins were eluted from the beads in 50 μL elution buffer (200 mM NaCl,
50 mM Tris-HCl pH 8, 2% SDS, and 1 mM Biotin in water) for 30 min at 60 °C51.
Protein samples were resolved by SDS–PAGE, transferred to nitrocellulose and
probed with the indicated antibodies.
Immunofluorescence. Cells were fixed with BD Cytofix (BD Bioscience) for 10
min at 22 °C, washed twice with dPBS (Cellgro) and permeabilized in dPBS + 0.2%
Triton X-100 for 1 h at 22 °C followed by two additional dPBS washes. For antigen
recovery, required for SP5 staining, cells were incubated with dPBS + 1% Sodium
Dodecyl Sulfate for 10 min at 22 °C and washed three times with dPBS. Cells were
blocked by treatment with buffer (dPBS, 0.5 mM EDTA, 1% BSA) for 30 min at 22
°C. Primary antibodies (see below) were diluted in buffer and incubated with cells
overnight at 4 °C, followed by two washes with FACS buffer. Secondary antibodies
were diluted in buffer and incubated with cells for 1 h at
22 °C, followed by two washes with FACS buffer. Nuclei were labeled with Hoechst
33342 (Roche) diluted 1:10,000 in buffer, followed by two washes with buffer. Cells
were imaged on a Leica SPE confocal microscope.
Flow cytometry. Cells were dissociated with Accutase, blocked with FACS buffer
(dPBS, 0.5 mM EDTA, 1% BSA), and stained with fluorophore-conjugated primary
antibodies (see below) according to manufacturer recommendations. Fluorescence
was measured on BD FACSCanto II and BD LSRFortessa instruments, and analysis
was performed with Flowing Software flow cytometry analysis suite (http://www.
flowingsoftware.com).
Antibodies. Primary antibodies for immunoblotting: Rabbit anti-SP5 1:250
(Abcam ab209385); Mouse anti-SP1 1:500 (Santa Cruz Biotechnology sc-17824);
Mouse anti-β-actin 1:1000 (Sigma A2228); Mouse anti-β-catenin 1:1000 (Sigma-
Aldrich C7207); Rabbit anti-LEF1 1:1000 (Cell Signaling Technology C12A5).
Secondary antibodies for immunoblotting: goat anti-Rabbit-IgG-HRP 1:5000
(Santa Cruz Biotechnology sc-2004); Goat anti-Mouse-IgG-HRP 1:5000 (Santa
Cruz Biotechnology sc-2005). Primary antibody for IF: Rabbit anti-SP5 1:50
(Abcam ab209385), Goat anti-SOX17 1:100 (R&D Systems, AF1924). Secondary
antibody for IF: Alexa Fluor 647-Goat anti-Rabbit 1:200 (Thermo Fisher Scientific
A-21244); Alexa Fluor 647-Donkey anti-Mouse 1:200 (Thermo Fisher Scientific,
A31571); Alexa Fluor 488-Chicken anti-Goat 1:200 (Thermo Fisher Scientific,
A21467). Primary antibody for flow cytometry: APC-Mouse anti-CD184 1:200 (BD
Biosciences BD555976), mouse anti-FZD7 1:100 (described in ref. 7 and available
upon request from K.W.), Alexa Fluor 488 Mouse anti-Human TRA-1-81 1:100
(Biolegend, 330710); PE Mouse anti-Human SSEA4 1:100 (Biolegend, 330406).
Antibodies for ChIP: Rabbit anti-SP5 polyclonal serum (custom generated by
Abcam; affinity purified against a GST fusion protein with SP5 residues 1–129);
Mouse anti-SP1 (Santa Cruz Biotechnology sc-17824); Rabbit anti-Trimethyl
Histone H3 (Lysine 4) (EMD Millipore 04-745); Mouse anti-Dimethyl Histone H3
(Lysine 4) (EMD Millipore 05-1338); Mouse anti-Trimethyl Histone H3 (Lysine
27) (Active Motif 61017); Rabbit anti-Dimethyl Histone H3 (Lysine 27) (Cell
Signaling 9728).
Microscopy. Phase contrast microscopy was performed using Leica, Zeiss, and
EVOS (Life Technologies) inverted fluorescence microscopes. Image analysis and
manipulation was performed with ImageJ and GIMP. Histological sections were
imaged on a Zeiss Axioskop upright microscope. Confocal microscopy was per-
formed using a Leica SPE microscope.
RNA-Seq. Total RNA was prepared from cells using the RNeasy Plus column
purification kit (Qiagen) and depleted of ribosomal RNA. After ligating adaptors,
fragmented RNA was converted to first strand cDNA using ArrayScript Reverse
Transcriptase (Ambion), size selected (100–200 bp) by gel electrophoresis, and
PCR amplified using adaptor-specific primers. Sequencing was executed on an
Illumina HiSeq 2000. TopHat and Cufflinks52, 53 were used to perform differential
gene expression analysis of RNA-seq experiments. Briefly, sequencing reads were
quality filtered, mapped, and aligned to the reference human genome (hg19) with
TopHat and Cuffdiff was used to calculate gene expression levels as reads per
thousand transcript bases per million reads mapped (RPKM). Statistically
significant changes in gene expression were obtained from RPKM values. Genes
were clustered by expression pattern and principal component analysis was per-
formed (Genesis). GO was performed (HOMER).
ChIP-PCR, ChIP-Seq, and downstream analyses. For SP1 and SP5 ChIP
experiments, chromatin immunoprecipitations were performed according to the
protocols developed by the Myers’ lab (http://hudsonalpha.org/protocols; Myers
Lab ChIP-Seq Protocol v041610). HESCs (H1/WA01) were treated or not treated
with Wnt3a for 24 h. Formaldehyde (Sigma-Aldrich) was added to each plate to a
final concentration of 1%, 10 min at room temperature. An additional plate of cells
grown in parallel was used to determine cell number and an equivalent of 107 cells
were used per ChIP. To stop crosslinking, glycine was added to a final con-
centration of 0.125 M. Cross-linked cells were washed once with 1× PBS and then
lysed on ice in Farnham lysis buffer (5 mM PIPES, pH 8, 85 mM KCl, 0.5%
IGEPAL CA-630) (Sigma-Aldrich) freshly supplemented with and Protease Inhi-
bitor Cocktail (Sigma-Aldrich). Cells were detached from the plate with a cell
scraper, transferred to a conical tube and pelleted at 1000×g, 5 min, 4 °C. Cell
pellets were resuspended in 1 mL Farnham lysis buffer supplemented with Protease
Inhibitor Cocktail and pelleted at 1000×g, 5 min, 4 °C, then resuspended in 300 μL
RIPA buffer (1× PBS, 1% IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1 % SDS)
supplemented with Protease Inhibitor Cocktail. Samples were sonicated in a
Bioruptor (Diagenode), 15 min at high setting, 30 s on, 30 s off, 4 °C. Samples were
centrifuged 20,000×g, 15 min, 4 °C and supernatants were flash frozen in liquid
nitrogen and stored at −80 °C until immunoprecipitation. For histone modification
ChIP experiments (H3K4me2, H3K4me3, H3K27me2, H3K27me3), crosslinking
was performed in identical fashion but downstream processing was different: cells
were lysed for 10 min on ice in lysis buffer (1% SDS, 50 mM Tris-HCl pH 8, 20 mM
EDTA + Roche Complete Protease Inhibitor Cocktail). Lysates were diluted to
600 µL with TE buffer (10 mM Tris-HCl pH 8.0, 1 mM EDTA) and sonicated with
a Branson Sonifier for 10 cycles (15 s on, 45 s off, 30% Power). Lysates were
clarified by centrifugation (1000×g, 4 °C, 10 min) and supernatant chromatin
concentrations were estimated by OD260; 20 µL of sample was saved for input.
Samples were diluted to 0.5 mg mL−1 in dilution buffer (16.7 mM Tris-HCl pH 8,
0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 167 mM NaCl) and adjusted to
10% glycerol. Samples were flash frozen in liquid nitrogen and stored at −80 °C
until immunoprecipitation. For each chromatin immunoprecipitation, 150 µL
Dynabeads Protein G (Life Technologies, Carlsbad, CA) were resuspended by
vortexing and washed three times with 1 mL PBS + bovine serum albumin (5 mg
mL−1). Beads were resuspended in a final volume of 150 µL of PBS + BSA +
5 µg of antibody and incubated with rotation at 4 °C for 8 h. Beads were washed an
additional three times with 1 mL PBS + BSA. About 1000 µL chromatin was
adjusted with 300 µL ChIP master mix buffer (1% Triton X-100, 0.1% Deoxycholic
acid, Roche Complete Protease Inhibitor Cocktail in TE buffer) and added directly
to the antibody-bound beads, followed by incubation with rotation at 4 °C for at
least 10 h. Supernatant was removed and beads were washed five times with 1 mL
of RIPA buffer (50 mM HEPES pH 8.0, 1% IGEPAL CA-630, 0.7% Deoxycholic
Acid, 500 mM LiCl, 1 mM EDTA, and Roche Complete Protease Inhibitor Cock-
tail) and once with 1 mL of TE buffer. About 150 µL of elution buffer (10 mM Tris-
HCl pH 8, 1 mM EDTA, 1% SDS) was added directly to the beads. Beads were
vortexed briefly and incubated at 65 °C for 20 min at a mixing frequency of 1300
RPM in a Thermomixer (Eppendorf). Eluted chromatin was removed from the
beads and incubated at 65 °C overnight to reverse crosslinks. Chromatin was
diluted with 250 µL TE buffer and treated with RNase A (0.2 mg mL−1, 37 °C, 1 h)
and Proteinase K (0.4 mg mL−1, 55 °C, 1 h). Chromatin was purified using the
Zymo ChIP Clean and Concentrator Kit (Zymo Research, Irvine, CA) and used
directly for PCR or sent for library prep and sequencing. PCR primers are provided
in Supplementary Table 1. Libraries from immunoprecipitated chromatin were
prepared by the nucleic acid core of The Scripps Research Institute and sequenced
on a HiSeq instrument (Illumina, San Diego, CA) by following the manufacturer’s
instruction. Reads were filtered by quality and trimmed and mapped to the genome
(Bowtie 2). Random down sampling was used to normalize all tracks to have equal
read number. Peaks were called (MACS20), BedGraph tracks were generated
(BEDTools) and visualized on the Santa Cruz Genome Browser. Motif, coverage,
annotation, and GO analyses were performed (HOMER). Venn diagrams were
generated (BioVenn).
Data availability. The RNA-seq and ChIP-seq data discussed in this publication
have been deposited in NCBI’s Gene Expression Omnibus and are accessible
through GEO Series accession number GSE103175. All data pertinent to this study
are available in Supplementary Information. Additional information on these data
is available from the corresponding authors.
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